Le Lézard
Classified in: Health, Science and technology

Introduction to the In-Vitro Diagnostic Regulation (IVDR) Online Training Course (November 3-4, 2022) - ResearchAndMarkets.com


The "Introduction to the In-Vitro Diagnostic Regulation (IVDR) Training Course" conference has been added to ResearchAndMarkets.com's offering.

The In-Vitro Diagnostic Regulation (EU) 2017/746, which came into force in May 2017 with a transition period of five years, is intended to strengthen the current approval system for in-vitro diagnostics and makes substantial changes to the existing IVD Directive (98/79/EC) legislation.

The Regulation introduces a new risk-rule classification system based on the Global Harmonization Task Force (GHTF) rules which, for the first time, takes patient impact into consideration. This will have a significant impact on all manufacturers of IVDs as about 80 per cent of all devices will now require some form of conformity assessment by a Notified Body.

This seminar will clarify the requirements applicable to in-vitro diagnostic devices under the new Regulation, highlight the major changes to responsibility and product data expectations and provide a thorough understanding of the impact on the industry.

Practical workshops over the two days will help consolidate the information provided.

Who Should Attend:

Key Topics Covered:

Introduction to IVDs

Historical overview of the current IVD Directive (98/79/EC)

Introduction to IVD Regulation (EU) 2017/746

Notified Bodies

IVD Regulation - key changes

Compiling the technical documentation for an IVD

Labelling requirements and strategies

ISO 13485:2016

Risk-based classification

Workshop: Product classification

Risk management

Workshop: Risk management

Clinical evidence and common specifications

Vigilance and PMS

Case studies: Reporting/recalls

Key timelines and practical considerations

Discussion: Preparing a roadmap for transition

Speakers:

Nancy Consterdine
Consultant
UL, IVDeology Ltd

Nancy Consterdine. This MDTI expert is a joint director in her own consultancy specialising in global regulatory affairs strategy and compliance for in vitro diagnostics and medical devices, focusing on the transition to the new IVD/Medical Device Regulations, MDSAP and ISO13485:2016.

She has over 30 years in the IVD industry and in previous roles has been responsible for designing, reviewing and maintaining regulatory frameworks for self-declared and annex II list products. Also identifying regulatory strategies around global submissions (EU, FDA, Health Canada, TGA, Russia, Latin America and China). She has a special interest in labelling and UDI requirements.

Stuart Angell
Director
IVDeology Ltd

Stuart Angell. This MDTI expert is a joint director in his own consultancy specialising in global regulatory affairs strategy and compliance for in vitro diagnostics and medical devices focusing on the transition to the new IVD/Medical Device Regulations, MDSAP and ISO13485:2016.

He has over 15 years in the IVD industry and in previous roles has been responsible for designing, reviewing and maintaining regulatory frameworks for self-declared and annex list II products including technical documentation for EU and global submissions (FDA, Health Canada, TGA, Russia, Latin America). He has an excellent understanding of risk management, Post Market Surveillance (PMS) and vigilance.

For more information about this conference visit https://www.researchandmarkets.com/r/van985

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


These press releases may also interest you

at 16:15
Forge Global Holdings, Inc. ("Forge") , a leading provider of marketplace infrastructure, data services and technology solutions for private market participants, today announced that it will report First Quarter Fiscal Year 2024 financial results on...

at 16:15
ServiceNow , the leading digital workflow company making the world work better for everyone, today announced financial results for its first quarter ended March 31, 2024, with subscription revenues of $2,523 million in Q1 2024, representing 25%...

at 16:12
Qohash today announced a $17.4 million Series B investment led by Fonds de solidarité FTQ, with participation from Export Development Canada (EDC) and existing investor Desjardins Capital. Since the last round of funding, Qohash has achieved...

at 16:10
Pegasystems Inc. , the leading enterprise AI decisioning and workflow automation platform provider, released its financial results for the first quarter of 2024. "In Q1, we released Pega GenAI BlueprintTM, a revolutionary technology that massively...

at 16:10
Brightcove Inc. , the world's most trusted streaming technology company, today announced it will report its first quarter fiscal year 2024 results for the period ended March 31, 2024, after the U.S. financial markets close on May 8, 2024. In...

at 16:10
Acadia Pharmaceuticals Inc. today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 8,...



News published on and distributed by: